Literature DB >> 33584247

Identification of Heterogeneous Subtypes of Mild Cognitive Impairment Using Cluster Analyses Based on PET Imaging of Tau and Astrogliosis.

Hyun Jeong Lee1, Eun-Chong Lee2, Seongho Seo3, Kwang-Pil Ko4, Jae Myeong Kang5, Woo-Ram Kim6, Ha-Eun Seo6, Sang-Yoon Lee3, Yeong-Bae Lee7, Kee Hyung Park7, Byeong Kil Yeon5, Nobuyuki Okamura8, Duk L Na9,10, Joon-Kyung Seong2,11,12, Young Noh7,13.   

Abstract

Background: Mild cognitive impairment (MCI) is a condition with diverse causes and clinical outcomes that can be categorized into subtypes. [18F]THK5351 has been known to detect reactive astrogliosis as well as tau which is accompanied by neurodegenerative changes. Here, we identified heterogeneous groups of MCI patients using THK retention patterns and a graph theory approach, allowing for the comparison of risk of progression to dementia in these MCI subgroups.
Methods: Ninety-seven participants including 60 MCI patients and individuals with normal cognition (NC, n = 37) were included and undertook 3T MRI, [18F]THK5351 PET, and detailed neuropsychological tests. [18F]Flutemetamol PET was also performed in 62 participants. We calculated similarities between MCI patients using their regional standardized uptake value ratio of THK retention in 75 ROIs, and clustered subjects with similar retention patterns using the Louvain method based on the modularity of the graph. The clusters of patients identified were compared with an age-matched control group using a general linear model. Dementia conversion was evaluated after a median follow-up duration of 34.6 months.
Results: MCI patients were categorized into four groups according to their THK retention patterns: (1) limbic type; (2) diffuse type; (3) sparse type; and (4) AD type (retention pattern as in AD). Subjects of the limbic type were characterized by older age, small hippocampal volumes, and reduced verbal memory and frontal/executive functions. Patients of the diffuse type had relatively large vascular burden, reduced memory capacity and some frontal/executive functions. Co-morbidity and mortality were more frequent in this subgroup. Subjects of the sparse type were younger and declined only in terms of visual memory and attention. No individuals in this subgroup converted to dementia. Patients in the AD type group exhibited the poorest cognitive function. They also had the smallest hippocampal volumes and the highest risk of progression to dementia (90.9%).
Conclusion: Using cluster analyses with [18F]THK5351 retention patterns, it is possible to identify clinically-distinct subgroups of MCI patients and those at greater risk of progression to dementia.
Copyright © 2021 Lee, Lee, Seo, Ko, Kang, Kim, Seo, Lee, Lee, Park, Yeon, Okamura, Na, Seong and Noh.

Entities:  

Keywords:  THK; cluster analysis; mild cognitive impairment; positron emission tomography; tau

Year:  2021        PMID: 33584247      PMCID: PMC7874013          DOI: 10.3389/fnagi.2020.615467

Source DB:  PubMed          Journal:  Front Aging Neurosci        ISSN: 1663-4365            Impact factor:   5.750


  50 in total

1.  Different partial volume correction methods lead to different conclusions: An (18)F-FDG-PET study of aging.

Authors:  Douglas N Greve; David H Salat; Spencer L Bowen; David Izquierdo-Garcia; Aaron P Schultz; Ciprian Catana; J Alex Becker; Claus Svarer; Gitte M Knudsen; Reisa A Sperling; Keith A Johnson
Journal:  Neuroimage       Date:  2016-02-23       Impact factor: 6.556

2.  Assessment of Extent and Role of Tau in Subcortical Vascular Cognitive Impairment Using 18F-AV1451 Positron Emission Tomography Imaging.

Authors:  Hee Jin Kim; Seongbeom Park; Hanna Cho; Young Kyoung Jang; Jin San Lee; Hyemin Jang; Yeshin Kim; Ko Woon Kim; Young Hoon Ryu; Jae Yong Choi; Seung Hwan Moon; Michael W Weiner; William J Jagust; Gil D Rabinovici; Charles DeCarli; Chul Hyoung Lyoo; Duk L Na; Sang Won Seo
Journal:  JAMA Neurol       Date:  2018-08-01       Impact factor: 18.302

3.  Anatomical heterogeneity of Alzheimer disease: based on cortical thickness on MRIs.

Authors:  Young Noh; Seun Jeon; Jong Min Lee; Sang Won Seo; Geon Ha Kim; Hanna Cho; Byoung Seok Ye; Cindy W Yoon; Hee Jin Kim; Juhee Chin; Kee Hyung Park; Kenneth M Heilman; Duk L Na
Journal:  Neurology       Date:  2014-10-24       Impact factor: 9.910

4.  Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy.

Authors:  A Ishiki; R Harada; N Okamura; N Tomita; C C Rowe; V L Villemagne; K Yanai; Y Kudo; H Arai; S Furumoto; M Tashiro; K Furukawa
Journal:  Eur J Neurol       Date:  2016-10-31       Impact factor: 6.089

5.  Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment.

Authors:  Angela L Guillozet; Sandra Weintraub; Deborah C Mash; M Marsel Mesulam
Journal:  Arch Neurol       Date:  2003-05

Review 6.  Advances in the development of tau PET radiotracers and their clinical applications.

Authors:  Nobuyuki Okamura; Ryuichi Harada; Katsutoshi Furukawa; Shozo Furumoto; Tetsuro Tago; Kazuhiko Yanai; Hiroyuki Arai; Yukitsuka Kudo
Journal:  Ageing Res Rev       Date:  2016-01-21       Impact factor: 10.895

7.  Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography.

Authors:  J Saura; J M Luque; A M Cesura; M Da Prada; V Chan-Palay; G Huber; J Löffler; J G Richards
Journal:  Neuroscience       Date:  1994-09       Impact factor: 3.590

8.  Tau positron emission tomographic imaging in aging and early Alzheimer disease.

Authors:  Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling
Journal:  Ann Neurol       Date:  2015-12-15       Impact factor: 10.422

9.  PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes.

Authors:  Sonja Schönecker; Matthias Brendel; Carla Palleis; Leonie Beyer; Günter U Höglinger; Elisabeth Schuh; Boris-Stephan Rauchmann; Julia Sauerbeck; Guido Rohrer; Stefan Sonnenfeld; Katsutoshi Furukawa; Aiko Ishiki; Nobuyuki Okamura; Peter Bartenstein; Marianne Dieterich; Kai Bötzel; Adrian Danek; Axel Rominger; Johannes Levin
Journal:  Front Aging Neurosci       Date:  2019-09-11       Impact factor: 5.750

10.  Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm.

Authors:  Konstantinos Chiotis; Laure Saint-Aubert; Irina Savitcheva; Vesna Jelic; Pia Andersen; My Jonasson; Jonas Eriksson; Mark Lubberink; Ove Almkvist; Anders Wall; Gunnar Antoni; Agneta Nordberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-21       Impact factor: 9.236

View more
  2 in total

1.  [18F]THK-5351 PET Patterns in Patients With Alzheimer's Disease and Negative Amyloid PET Findings.

Authors:  Minyoung Oh; Jungsu S Oh; Seung Jun Oh; Sang Ju Lee; Jee Hoon Roh; Woo Ram Kim; Ha-Eun Seo; Jae Myeong Kang; Sang Won Seo; Jae-Hong Lee; Duk L Na; Young Noh; Jae Seung Kim
Journal:  J Clin Neurol       Date:  2022-07       Impact factor: 2.566

Review 2.  PET imaging of reactive astrocytes in neurological disorders.

Authors:  Yu Liu; Han Jiang; Xiyi Qin; Mei Tian; Hong Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-12-07       Impact factor: 9.236

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.